Successful Establishment of a Nipple Fissure Model: Protocol, Validation, and Preclinical Efficacy T

The successful construction of a nipple fissure model provides a scientifically validated preclinical platform for evaluating the protective and wound-healing efficacy of nipple care creams, lanolin ointments, and wound dressings intended for lactating women. By combining standardized lesion induction, histopathological confirmation, and quantitative healing endpoints in an accredited laboratory setting, this model enables manufacturers to substantiate product claims and support regulatory submissions. This article outlines the model construction protocol, validation criteria, test items, methods, and practical applications.

Technical Overview

Nipple fissure, clinically referred to as cracked nipple or nipple rhagades, is one of the most frequent complications of lactation, reported by a large proportion of breastfeeding women during the early postpartum period. The condition is characterized by epidermal erosion, linear fissuring, desquamation, pain, and an elevated risk of secondary infection and mastitis, and it is a leading cause of premature breastfeeding discontinuation.

A nipple fissure model construction test is a preclinical study in which characteristic nipple lesions are induced in laboratory animals under controlled, reproducible conditions, followed by validation against predefined morphological, histological, and functional criteria. Once the model is successfully established, it serves as a robust platform for assessing how topical formulations accelerate wound closure, restore skin barrier function, and reduce inflammation. The successful model construction trial confirms that lesion severity, reproducibility, and spontaneous healing kinetics fall within the acceptance ranges required for statistically powered efficacy studies, in accordance with animal welfare principles and relevant frameworks such as the ISO 10993 series and GB/T 16886 series for biological evaluation.

Testing Samples

Nipple Care Creams and Lanolin-Based Ointments

Purified lanolin products, petrolatum-based barrier ointments, and emollient creams formulated for breastfeeding mothers can be evaluated for their ability to prevent lesion progression and promote re-epithelialization in the established model.

Medical Wound Dressings and Barrier Devices

Hydrogel pads, hydrocolloid dressings, silicone barrier films, and absorbent nursing pads classified as medical devices can be tested for lesion protection, exudate management, and healing acceleration.

Herbal, Botanical, and Functional Cosmeceutical Preparations

Plant extracts, traditional medicine ointments, and functional skincare formulations intended for damaged or compromised nipple skin can be assessed for efficacy and local tolerability.

Cleansing and Moisturizing Products

Nipple cleansers, moisturizing gels, and repair serums can be evaluated for barrier-repair performance and compatibility with the healing process in the model system.

Testing Items

The successful model construction trial and subsequent efficacy evaluations typically encompass the following test items:

• Model validation parameters: lesion incidence rate, severity grading of erythema, erosion, fissuring, crusting, and desquamation, and inter-animal reproducibility.
• Wound healing endpoints: lesion area measurement by image analysis, wound contraction rate, re-epithelialization rate, and time to complete healing.
• Histopathological evaluation: hematoxylin and eosin staining of nipple and surrounding areolar tissue, including epidermal thickness, inflammatory cell infiltration, collagen deposition, and dermal remodeling scores.
• Skin barrier function: transepidermal water loss (TEWL) and stratum corneum hydration measurements.
• Inflammatory and biochemical markers: local levels of interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) determined by immunoassay.
• Safety observations: local irritation assessment, daily clinical observation, body weight monitoring, and gross pathology examination.

Testing Methods

Model Induction Protocol

The model is typically established in lactating Sprague-Dawley rats during the early postpartum lactation window, or in New Zealand white rabbits where a larger lesion area is required. Lesions are induced by a standardized combination of controlled mechanical stimulation, simulating the repetitive suckling friction and negative-pressure trauma that occur during breastfeeding, optionally combined with controlled hydration-desiccation cycles. Induction parameters such as contact pressure, cycle duration, session frequency, and treatment days are fixed in the validated protocol to ensure uniform lesion severity across animals.

Grouping and Dosing Design

Studies generally include a sham control group, a model control group receiving no treatment or vehicle only, a positive control group treated with a recognized reference ointment, and one or more test-article groups at different dose levels or application frequencies. Test articles are applied topically to the nipple area once or twice daily for a predefined period, commonly 7 to 14 days, with lesion progression documented daily.

Endpoints and Measurements

Lesions are scored daily using a standardized gross morphology grading scale, and lesion dimensions are quantified by calibrated digital imaging. On scheduled endpoints, tissue specimens are collected for histopathological examination and barrier function measurement, and skin tissue homogenates are analyzed for inflammatory cytokines. Data are analyzed statistically, with analysis of variance or rank-based tests used to compare healing outcomes between groups, confirming whether the test article significantly accelerates recovery relative to the model control.

Model Success Criteria

Model construction is judged successful when the lesion incidence rate, mean severity score, histological confirmation of epidermal disruption with dermal inflammatory response, and coefficient of variation in lesion severity all meet the predefined acceptance criteria, ensuring the model is sensitive enough to detect treatment effects. All procedures are conducted under institutional animal care and ethics approval, applying the 3R principles (replacement, reduction, refinement) and reported in alignment with ARRIVE reporting guidelines, with local tolerability referenced to ISO 10993-23 and GB/T 16886.23 irritation principles and OECD Test Guideline 404 methodology where applicable.

Applications

The successfully established nipple fissure model supports a wide range of product development and regulatory activities:

• Efficacy substantiation for marketing claims such as "promotes repair," "soothes cracked skin," and "supports skin barrier recovery" on nipple care products.
• Preclinical efficacy data packages for medical device registration and cosmetic claim substantiation dossiers.
• Formula optimization and screening of active ingredients, excipients, and delivery formats during research and development.
• Comparative benchmarking of a candidate product against marketed reference products or competitor formulations.
• Dose-finding and application-frequency studies to define the recommended use regimen for the final product.
• Combination testing with biocompatibility programs under the ISO 10993 and GB/T 16886 series to build a complete safety and efficacy profile.

FAQ

Q1: What animal species are used to construct the nipple fissure model?

Lactating Sprague-Dawley rats are the most commonly used species because their lactation physiology and nipple structure support reproducible lesion induction; New Zealand white rabbits may be selected when larger tissue samples or greater lesion areas are needed for analysis.

Q2: How is successful model construction confirmed?

Success is confirmed by a combination of gross lesion scoring, histopathological verification of epidermal disruption and dermal inflammation, acceptable inter-animal reproducibility of lesion severity, and demonstration that the lesions heal predictably over the observation window, allowing treatment effects to be detected with statistical significance.

Q3: How long does a typical study take?

The model construction and validation phase generally requires several weeks of protocol optimization, while a standard efficacy study including induction, treatment, and endpoint evaluation typically spans two to four weeks, depending on the study design and regulatory objectives.

Q4: Can the study results be used for regulatory submissions?

Yes. Data generated in the validated model under Good Laboratory Practice-aligned quality systems at accredited third-party laboratories are widely used to support medical device registrations and cosmetic efficacy claim dossiers in multiple jurisdictions.

Q5: What sample forms can be tested?

Ointments, creams, gels, lotions, liquids, sprays, films, and wound dressings can all be evaluated, provided the test article is suitable for topical application to the nipple area and available in sufficient quantity for the required dose groups.